It was shown that rs28714259 disrupts the GR-mediated protective signaling pathway against doxorubicin-induced cardiotoxicity and reduction in cardiac contractility, dysregulates cardiac hypertrophy signaling, mitochondrial function, and glucose metabolism, which interferes with cardiomyocyte survival following doxorubicin using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in vitro [232]. The gene discussed is NR3C1; the disease is cardiac hypertrophy.